Growth Metrics

Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2016 - 2025)

Jazz Pharmaceuticals has reported Deferred Taxes over the past 14 years, most recently at -$63.3 million for Q4 2025.

  • Quarterly Deferred Taxes fell 2588.28% to -$63.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$445.0 million through Dec 2025, down 113.59% year-over-year, with the annual reading at -$445.0 million for FY2025, 113.59% down from the prior year.
  • Deferred Taxes was -$63.3 million for Q4 2025 at Jazz Pharmaceuticals, up from -$271.4 million in the prior quarter.
  • Over five years, Deferred Taxes peaked at $190.7 million in Q2 2021 and troughed at -$271.4 million in Q3 2025.
  • The 5-year median for Deferred Taxes is -$64.5 million (2022), against an average of -$56.8 million.
  • Biggest five-year swings in Deferred Taxes: surged 1114.78% in 2021 and later crashed 2588.28% in 2025.
  • Tracing JAZZ's Deferred Taxes over 5 years: stood at -$27.4 million in 2021, then tumbled by 430.67% to -$145.4 million in 2022, then surged by 75.31% to -$35.9 million in 2023, then surged by 93.44% to -$2.4 million in 2024, then crashed by 2588.28% to -$63.3 million in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$63.3 million, -$271.4 million, and -$66.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.